DFO
RVMD icon

Duquesne Family Office’s Revolution Medicines RVMD Stock Holding History

Duquesne Family Office’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.8M Buy
399,587
+83,727
+27% +$12.2M 1.44% 22
2026
Q1 		$30.7M Buy
+315,860
New +$31.9M 0.91% 26

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Duquesne Family Office's RVMD Position: Q2 2026 in Review

Duquesne Family Office increased its Revolution Medicines (RVMD) stake by 27% in Q2 2026, buying an estimated $12.2M and bringing the position to 399,587 shares worth $74.8M. The position accounts for 1.44% of the portfolio, ranked #22.

Duquesne Family Office first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Duquesne Family Office held 399,587 shares of Revolution Medicines worth $74.8M as of Q2 2026.
  • Duquesne Family Office bought 83,727 Revolution Medicines shares in Q2 2026, an estimated $12.2M.
  • Revolution Medicines made up 1.44% of Duquesne Family Office's portfolio in Q2 2026, its #22 holding.
  • Duquesne Family Office first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Duquesne Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.